RVF001 / University of Oxford - LARVOL DELTA

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) (clinicaltrials.gov) - P2 | N=240 | Active, not recruiting | Sponsor: University of Oxford | Recruiting ➔ Active, not recruiting

Enrollment closed • Respiratory Diseases

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial. (PubMed, Lancet Infect Dis) - P1 | "A single dose of ChAdOx1 RVF vaccine seemed to be safe, tolerable, and immunogenic in healthy adults in an RVF-endemic setting, eliciting humoral and cellular immunity. Further evaluation of the 5·0 × 1010 dose in larger and more diverse populations in areas susceptible to outbreaks is warranted."

Journal • P1 data • Fatigue • Musculoskeletal Pain • Pain • Respiratory Diseases • IFNG

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: University of Oxford | Initiation date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Nov 2025 ➔ Mar 2026

Trial initiation date • Trial primary completion date • Respiratory Diseases

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: University of Oxford

New P2 trial • Respiratory Diseases

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. (PubMed, Lancet Infect Dis) - P1 | "ChAdOx1 RVF was safe, well tolerated, and immunogenic when administered as a single dose in this study population. The data support further clinical development of ChAdOx1 RVF for human use."

Journal • P1 data • Fatigue • Gastrointestinal Disorder • Pain • Respiratory Diseases • IFNG

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: University of Oxford | Recruiting ➔ Completed

Trial completion • Respiratory Diseases

Determining the acceptability of a novel One Health vaccine for Rift Valley Fever prior to phase II/III clinical trials in Uganda. (PubMed, One Health) - "A promising candidate, ChAdOx1 RVF vaccine, has been developed for use in both humans and animals, and has undergone field trials in livestock in Kenya...45% of those interviewed said that they would not be willing to receive a One Health vaccine and a further 13% were unsure whether or not they would be happy to receive such a vaccine. Semi-structured interviews were conducted to explore their reasons for and against the acceptability of a novel One Health vaccine to highlight potential barriers to deployment once a vaccine candidate for RVF becomes available."

Journal • P2/3 data • Respiratory Diseases

Safety and immunogenicity from a phase I clinical trial of the Rift Valley fever vaccine, ChAdOx1 RVF, in UK adults (ASTMH 2022) - "The COVID-19 pandemic has demonstrated that a ChAdOx1 vaccine can be manufactured cheaply and at scale. Together with its established efficacy in livestock, ChAdOx1 RVF vaccine could become a crucial tool to mitigate against the burden of RVF disease, as part of a One Health vaccine strategy in humans and livestock."

Clinical • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: University of Oxford | Trial completion date: Jul 2022 ➔ Dec 2022 | Trial primary completion date: Jul 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Respiratory Diseases

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001) (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: University of Oxford | Recruiting ➔ Completed | Trial completion date: Nov 2021 ➔ Apr 2022 | Trial primary completion date: Nov 2021 ➔ Apr 2022

Trial completion • Trial completion date • Trial primary completion date • Respiratory Diseases

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: University of Oxford | Trial completion date: Feb 2022 ➔ Jul 2022 | Trial primary completion date: Feb 2022 ➔ Jul 2022

Trial completion date • Trial primary completion date • Respiratory Diseases

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001) (clinicaltrials.gov) - P1; N=15; Recruiting; Sponsor: University of Oxford; Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases